Chinese Academy of Medical Sciences: all 237 studies

Page 1 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal CancerNot yet recruitingNCT05484024Phase 2/3
• Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast CancerNot yet recruitingNCT05291910Phase 4
• Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world StudyNot yet recruitingNCT05287308Not applicable
• The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC PtsRecruitingNCT05074966Phase 3
• Hypofractionated Post Mastectomy Radiation With Two-Stage Expander/Implant ReconstructionRecruitingNCT05045287Not applicable
• Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior TherapiesNot yet recruitingNCT04994626Phase 2
• Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT04861467Phase 2
• Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour ResectionEnrolling by invitationNCT04762459Phase 3
• A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With ChemoradiotherapyRecruitingNCT04749394Phase 2
• Radiotherapy for Extracranial Oligometastatic Breast CancerRecruitingNCT04646564Phase 3
• The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic MonitoringRecruitingNCT04499794
• Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCLEnrolling by invitationNCT04491721
• Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT04437160Phase 2
• Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal CarcinomaRecruitingNCT03908372Phase 2/3
• A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast CancerNot yet recruitingNCT03854617Phase 2
• Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer PatientsRecruitingNCT03731442Phase 3
• How do Super Lean Subjects Keep Resistant to Body Weight Gain?RecruitingNCT03221322
• Optimization of Preoperative Treatment in Locally Advanced Rectal CancerRecruitingNCT02533271Phase 3
• Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric CancerAvailableNCT02209441
• Prevention of OM-85 on Bronchiectasis ExacerbationCompletedNCT01968421Phase 4Results posted
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast CancerStatus unknownNCT01928680Phase 2Results posted
• Safety Study of Capecitabine With Radiation in Elderly Rectal CancerCompletedNCT01584544Phase 1Results posted
• Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer PatientsCompletedNCT01268943Phase 1Results posted
• HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BCStatus unknownNCT05566457Phase 2
• Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerStatus unknownNCT05546255Phase 2
• Low-dose Radiotherapy in iNHLStatus unknownNCT05543070Phase 2
• AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCStatus unknownNCT05522894Phase 2
• A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid TumorsStatus unknownNCT05499715Phase 1
• Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic ResectionCompletedNCT05499195
• The Clinical Effect of Adaptive Posture-balance Cardiac Rehabilitation Exercise on Cardiovascular DiseasesCompletedNCT05496153Not applicable
• Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 ResectionStatus unknownNCT05460403
• Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI TechnologyStatus unknownNCT05441098
• Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABCStatus unknownNCT05343117
• A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial CarcinomaStatus unknownNCT05318339Phase 2
• FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
• Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)Status unknownNCT05216484Phase 3
• Temozolomide for Injection Combined With Epirubicin in First-line Treatment of LeiomyosarcomaStatus unknownNCT05204524Not applicable
• The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCsStatus unknownNCT05202275Phase 2
• Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in ChinaCompletedNCT05194371
• Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and AboveStatus unknownNCT05164731Phase 3
• Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and AboveStatus unknownNCT05163652Phase 3
• Neratinib Dose Escalation Regimen for HER2 Positive Early Breast CancerStatus unknownNCT05154396Phase 2
• Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
• Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast CancerStatus unknownNCT05089643Phase 2
• Characteristics and Treatment Trends of Young Breast Cancer in ChinaStatus unknownNCT05068115
• Real World Study of MPM in ChinaStatus unknownNCT05042557
• Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2
• Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerStatus unknownNCT05016869Phase 1/2
• Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABCStatus unknownNCT05000736
• Prophylactic Cranial Irradiation in Extensive-stage Small Cell Lung CancerStatus unknownNCT04947774
• TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or MetastasisStatus unknownNCT04888546Phase 1/2
• Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell CarcinomaStatus unknownNCT04851132Not applicable
• Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world StudyStatus unknownNCT04835324
• Sequence of Radiation and Targeted Therapy in Brain MetastasesCompletedNCT04832672
• A Real-world Clinical Study of Kapok InitiativeSuspendedNCT04735991Not applicable
• Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
• Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.Status unknownNCT04661696Phase 2
• The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19Status unknownNCT04659239Phase 3
• Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus InfectionStatus unknownNCT04626856Phase 1
• Online Noninvasive Assessment of Human Brain Death and Deep Coma by Near-infrared SpectroscopyStatus unknownNCT04623294
• Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyStatus unknownNCT04620837Phase 2
• PCI for Patients With ES-SCLC After RCT:a Prospective Randomized StudyStatus unknownNCT04535739Phase 3
• Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell LymphomaStatus unknownNCT04511351Not applicable
• Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell LymphomaCompletedNCT04509804
• Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung CancerStatus unknownNCT04500145Phase 3
• Comparison of Two Bending Angles for Nasotracheal Intubation With a Malleable Vedio StyletCompletedNCT04459481Not applicable
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPSStatus unknownNCT04447274Phase 2
• Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell LymphomaStatus unknownNCT04425824Phase 2
• Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04390958Phase 2
• A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal CancerStatus unknownNCT04380103Phase 1/2
• Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT04348032Phase 2
• Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLCStatus unknownNCT04304638
• Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast CancerStatus unknownNCT04289974
• Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal CarcinomaStatus unknownNCT04275986Phase 2
• A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal CancerCompletedNCT04247984Phase 2
• Purified Inactivated Japanese Encephalitis VaccineStatus unknownNCT04223037Phase 3
• Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast CancerStatus unknownNCT04194684Phase 2
• Tomotherapy for Leptomeningeal MetastasesCompletedNCT04178343Not applicable
• Tomotherapy as Primary Radiotherapy for Multipule Brain MetastasesCompletedNCT04178330Not applicable
• Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast CancerStatus unknownNCT04158505
• Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaStatus unknownNCT04140318Phase 2
• Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular CarcinomaCompletedNCT04072679Phase 1
• Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )Status unknownNCT04033172Phase 2
• Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Status unknownNCT04023916Phase 2
• Monitoring Efficacy of Radiotherapy in Lung Cancer and Esophageal CancerStatus unknownNCT04014465
• PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung CancerStatus unknownNCT03971214Phase 1
• Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCRStatus unknownNCT03947736
• A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast CancerStatus unknownNCT03939871Phase 2
• A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast CancerStatus unknownNCT03933982Phase 2
• Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast CancerStatus unknownNCT03933319Phase 2
• Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With OligometastasisStatus unknownNCT03927898Phase 2
• Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast CancerStatus unknownNCT03923179Phase 2
• Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast CancerStatus unknownNCT03923166Phase 2
• TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLCStatus unknownNCT03916913Not applicable
• Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal CarcinomaStatus unknownNCT03915132Phase 2
• The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair DeficiencyStatus unknownNCT03876886Phase 3
• Optical Assessment on Brain Death Via a Oxygen Supply ProcedureStatus unknownNCT03864887
• Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus VaccineStatus unknownNCT03821441Phase 3
• Hemodynamic Changes During Dry Cupping Therapy on Low Back PainStatus unknownNCT03816787Not applicable

← Chinese Academy of Medical Sciences overview and focus areas